New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - bimatoprost 0.3 mg/ml;   - eye drops, solution - 0.3 mg/ml - active: bimatoprost 0.3 mg/ml   excipient: citric acid monohydrate dibasic sodium phosphate heptahydrate hydrochloric acid purified water sodium chloride sodium hydroxide - indicated as monotherapy for the reduction of elevated intraocular pressure (iop) in patients with chronic glaucoma or ocular hypertension; or as adjunctive therapy in patients not adequately controlled on other agents.

Ireland - English - HPRA (Health Products Regulatory Authority)

abbvie limited - paricalcitol - solution for injection - 5 microgram(s)/millilitre - other anti-parathyroid agents; paricalcitol

Ireland - English - HPRA (Health Products Regulatory Authority)

abbvie limited - paricalcitol - solution for injection - 5 microgram(s)/millilitre - other anti-parathyroid agents; paricalcitol

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - bimatoprost 300 µg/ml;  ; timolol maleate 5 mg/ml;   - eye drops, solution - 300mcg/ml & 5mg/ml - active: bimatoprost 300 µg/ml   timolol maleate 5 mg/ml   excipient: citric acid monohydrate dibasic sodium phosphate heptahydrate hydrochloric acid purified water sodium chloride sodium hydroxide - indicated for the reduction of intraocular pressure (iop) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to monotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - upadacitinib hemihydrate 15.4mg equivalent to upadacitinib 15mg - modified release tablet - 15 mg - active: upadacitinib hemihydrate 15.4mg equivalent to upadacitinib 15mg excipient: colloidal silicon dioxide hypromellose magnesium stearate mannitol microcrystalline cellulose opadry purple 85f100091 tartaric acid - rinvoq is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis. rinvoq may be used as monotherapy or in combination with methotrexate or other conventional synthetic disease modifying anti-rheumatic drugs (csdmards).

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - upadacitinib hemihydrate 30.7mg equivalent to upadacitinib 30 mg - modified release tablet - 30 mg - active: upadacitinib hemihydrate 30.7mg equivalent to upadacitinib 30 mg excipient: colloidal silicon dioxide hypromellose magnesium stearate mannitol microcrystalline cellulose opadry red 85f150093 tartaric acid - rinvoq is indicated for the treatment of adults and adolescents 12 years and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - upadacitinib hemihydrate 46.1mg equivalent to upadacitinib 45 mg - modified release tablet - 45 mg - active: upadacitinib hemihydrate 46.1mg equivalent to upadacitinib 45 mg excipient: colloidal silicon dioxide hypromellose magnesium stearate mannitol microcrystalline cellulose opadry yellow 85f120063 tartaric acid - rinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - risankizumab 90 mg/ml;   - solution for injection - 75 mg/0.83ml - active: risankizumab 90 mg/ml   excipient: polysorbate 20 sodium succinate sorbitol succinic acid water for injection - psoriasis: skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - risankizumab 150 mg/ml;   - solution for injection - 150 mg/ml - active: risankizumab 150 mg/ml   excipient: glacial acetic acid polysorbate 20 sodium acetate trihydrate trehalose dihydrate water for injection - psoriatic arthritis: skyrizi is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to or are intolerant to one or more disease modifying antirheumatic drugs (dmards). skyrizi may be used as monotherapy or in combination with a conventional synthetic disease modifying antirheumatic drug (csdmard).

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - risankizumab 150 mg/ml;   - solution for injection - 150 mg/ml - active: risankizumab 150 mg/ml   excipient: glacial acetic acid polysorbate 20 sodium acetate trihydrate trehalose dihydrate water for injection - psoriatic arthritis: skyrizi is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to or are intolerant to one or more disease modifying antirheumatic drugs (dmards). skyrizi may be used as monotherapy or in combination with a conventional synthetic disease modifying antirheumatic drug (csdmard).